Company Profile
Virax Biolabs Stock Price, News & Analysis
- Ticker:
- VRAX
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United Kingdom and listed in the U
Stock performance
2.77 USD (-4.81%)
Close
Last updated: August 6, 2026
1.61M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, VRAX closed down 4.81% at $2.77. No new same-company headline was identified in the current news window.
Company overview
Business overview
Virax Biolabs is a diagnostics company focused on immune profiling and infectious-disease testing. Its business is centered on molecular and laboratory diagnostics rather than therapeutics.
Geographic Base and Sector Classification
Virax Biolabs is headquartered in the United Kingdom and listed in the U.S. market. It sits in diagnostics and medical devices rather than biotechnology.
Business Model Characteristics
The company depends on product adoption, test utilization, and commercialization in a competitive diagnostics market. Investors watch market access, product rollout, and operating execution.
Position Within the Biotechnology Landscape
Virax occupies the diagnostics layer of the healthcare stack. It is not a biotech drug name, but it belongs to the broader testing infrastructure that supports care decisions.
Future catalysts
Virax’s catalysts are infectious-disease and immune-profiling programs, plus any update that shows the platform can still create value. The next step matters because the company remains early.
Recent news
- 01
- 02
- 03
- 04
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Source: Virax Biolabs
- 05
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
Source: Virax Biolabs
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Virax Biolabs (VRAX)?
Virax Biolabs (VRAX) most recently closed at 2.77 USD, a -4.81% move versus the previous session.
What is the market cap of Virax Biolabs (VRAX)?
Virax Biolabs currently has a market capitalization of 1.61M USD on BioPharmSignal.
What does Virax Biolabs do?
Virax Biolabs is a diagnostics company focused on immune profiling and infectious-disease testing. Its business is centered on molecular and laboratory diagnostics rather than therapeutics.
On which exchange is VRAX stock listed?
Virax Biolabs (VRAX) is associated with NASDAQ, United Kingdom and listed in the U, MedTech.
What is Virax?
Virax’s catalysts are infectious-disease and immune-profiling programs, plus any update that shows the platform can still create value.
Which conditions is Virax Biolabs targeting with Virax?
Virax’s catalysts are infectious-disease and immune-profiling programs, plus any update that shows the platform can still create value.
How does Virax Biolabs describe recent progress with Virax?
Virax’s catalysts are infectious-disease and immune-profiling programs, plus any update that shows the platform can still create value.
What is Biolabs?
Virax Biolabs is a diagnostics company focused on immune profiling and infectious-disease testing.